Pierre Meulien joined IMI as Executive Director in September 2015. Previously, he was President and Chief Executive Officer of Genome Canada, a not-for-profit organisation that connects ideas and people across public and private sectors to find new uses for genomics and invests in large-scale science and technology to fuel innovation in key sectors, including health. Before joining Genome Canada in 2010, he served as Chief Scientific Officer for Genome British Columbia, where he promoted the organisation’s scientific strategy and he was founding CEO of the Dublin Molecular Medicine Centre which linked the three medical schools and six teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. Pierre Meulien also has experience of working in industry, having worked at Aventis Pasteur in Canada and France, and at French biotechnology company Transgene. He has a PhD in molecular biology from the University of Edinburgh and worked as a post-doctoral researcher at the Institut Pasteur in Paris.